496 related articles for article (PubMed ID: 33054456)
41. Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer.
Goyal L; Meric-Bernstam F; Hollebecque A; Valle JW; Morizane C; Karasic TB; Abrams TA; Furuse J; Kelley RK; Cassier PA; Klümpen HJ; Chang HM; Chen LT; Tabernero J; Oh DY; Mahipal A; Moehler M; Komatsu Y; Ahn DH; Epstein RS; Halim AB; Wacheck V; He Y; Liu M; Benhadji KA; Bridgewater JA;
Future Oncol; 2024 Jun; ():1-12. PubMed ID: 38884254
[TBL] [Abstract][Full Text] [Related]
42. Understanding drug resistance mechanisms in cholangiocarcinoma: assisting the clinical development of investigational drugs.
Marin JJ; Macias RI
Expert Opin Investig Drugs; 2021 Jul; 30(7):675-679. PubMed ID: 33934687
[No Abstract] [Full Text] [Related]
43. Ivosidenib: an investigational drug for the treatment of biliary tract cancers.
Angelakas A; Lamarca A; Hubner RA; McNamara MG; Valle JW
Expert Opin Investig Drugs; 2021 Apr; 30(4):301-307. PubMed ID: 33683991
[No Abstract] [Full Text] [Related]
44. Fibroblast growth factor receptor (FGFR) inhibitors: A review of a novel therapeutic class.
Weaver A; Bossaer JB
J Oncol Pharm Pract; 2021 Apr; 27(3):702-710. PubMed ID: 33375902
[TBL] [Abstract][Full Text] [Related]
45. Molecular targeted therapies: Ready for "prime time" in biliary tract cancer.
Lamarca A; Barriuso J; McNamara MG; Valle JW
J Hepatol; 2020 Jul; 73(1):170-185. PubMed ID: 32171892
[TBL] [Abstract][Full Text] [Related]
46. FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue.
Rizzo A; Ricci AD; Frega G; Di Federico A; Brandi G
Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):567-574. PubMed ID: 33787429
[No Abstract] [Full Text] [Related]
47. Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma.
Wu Q; Ellis H; Siravegna G; Michel AG; Norden BL; Fece de la Cruz F; Balasooriya ER; Zhen Y; Silveira VS; Che J; Corcoran RB; Bardeesy N
Clin Cancer Res; 2024 Jan; 30(1):198-208. PubMed ID: 37843855
[TBL] [Abstract][Full Text] [Related]
48. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors.
Bahleda R; Meric-Bernstam F; Goyal L; Tran B; He Y; Yamamiya I; Benhadji KA; Matos I; Arkenau HT
Ann Oncol; 2020 Oct; 31(10):1405-1412. PubMed ID: 32622884
[TBL] [Abstract][Full Text] [Related]
49. Molecular pathways and targeted therapy in cholangiocarcinoma.
Dabney RS; Khalife M; Shahid K; Phan AT
Clin Adv Hematol Oncol; 2019 Nov; 17(11):630-637. PubMed ID: 31851165
[TBL] [Abstract][Full Text] [Related]
50. Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications.
Amadeo E; Rossari F; Vitiello F; Burgio V; Persano M; Cascinu S; Casadei-Gardini A; Rimini M
Expert Rev Clin Pharmacol; 2023; 16(7):631-642. PubMed ID: 37387533
[TBL] [Abstract][Full Text] [Related]
51. Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma.
Lamarca A; Vogel A
ESMO Open; 2023 Dec; 8(6):102049. PubMed ID: 37922686
[No Abstract] [Full Text] [Related]
52. Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy.
Brown ZJ; Ruff SM; Pawlik TM
Expert Rev Anticancer Ther; 2023 Mar; 23(3):257-264. PubMed ID: 36744395
[TBL] [Abstract][Full Text] [Related]
53. Futibatinib: First Approval.
Syed YY
Drugs; 2022 Dec; 82(18):1737-1743. PubMed ID: 36441501
[TBL] [Abstract][Full Text] [Related]
54. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
Subbiah V; Iannotti NO; Gutierrez M; Smith DC; Féliz L; Lihou CF; Tian C; Silverman IM; Ji T; Saleh M
Ann Oncol; 2022 May; 33(5):522-533. PubMed ID: 35176457
[TBL] [Abstract][Full Text] [Related]
55. Infigratinib for the Treatment of Metastatic or Locally Advanced Cholangiocarcinoma With Known FGFR2 Gene Fusions or Rearrangements.
White K; Anwar AI; Jin K; Bollich V; Kelkar RA; Talbot NC; Klapper RJ; Ahmadzadeh S; Viswanath O; Varrassi G; Shekoohi S; Kaye AD
Cureus; 2023 Oct; 15(10):e46792. PubMed ID: 37954763
[TBL] [Abstract][Full Text] [Related]
56. Novel targeted treatment options for advanced cholangiocarcinoma.
Mahipal A; Kommalapati A; Tella SH; Lim A; Kim R
Expert Opin Investig Drugs; 2018 Sep; 27(9):709-720. PubMed ID: 30124336
[TBL] [Abstract][Full Text] [Related]
57. A drug safety evaluation of pemigatinib for advanced cholangiocarcinoma.
Uson PLS; Bearss J; Babiker HM; Borad M
Expert Opin Drug Saf; 2023; 22(8):637-641. PubMed ID: 37363820
[TBL] [Abstract][Full Text] [Related]
58. Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies.
Brandi G; Relli V; Deserti M; Palloni A; Indio V; Astolfi A; Serravalle S; Mattiaccio A; Vasuri F; Malvi D; Deiana C; Pantaleo MA; Cescon M; Rizzo A; Katoh M; Tavolari S
Sci Rep; 2024 Feb; 14(1):3136. PubMed ID: 38326380
[TBL] [Abstract][Full Text] [Related]
59. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma.
Arai Y; Totoki Y; Hosoda F; Shirota T; Hama N; Nakamura H; Ojima H; Furuta K; Shimada K; Okusaka T; Kosuge T; Shibata T
Hepatology; 2014 Apr; 59(4):1427-34. PubMed ID: 24122810
[TBL] [Abstract][Full Text] [Related]
60. Typing FGFR2 translocation determines the response to targeted therapy of intrahepatic cholangiocarcinomas.
Pu X; Ye Q; Cai J; Yang X; Fu Y; Fan X; Wu H; Chen J; Qiu Y; Yue S
Cell Death Dis; 2021 Mar; 12(3):256. PubMed ID: 33692336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
